A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Karger Publishers New Journal – Immune System

Expands Its Open Access Portfolio with an Up-and-Coming Publication for Basic and Applied Immunological Research

What To Know

  • With the launch of this new journal, the company seeks to fulfill a strong need in the scientific community for an open and up-and-coming forum for current basic and applied immunological research.
  • “Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann.

Karger Publishers’ new journal Immune System features Open Access-based original research and reviews reporting on translational and clinical studies encompassing all fields of immunology with the intention of bridging clinical research with preclinical and translational investigations. With the launch of this new journal, the company seeks to fulfill a strong need in the scientific community for an open and up-and-coming forum for current basic and applied immunological research. The journal will emphasize evidence-based clinical and laboratory research with statistically valid results that clearly help to advance the future of science.

The world-renowned editors-in-chief, Désirée Larenas-Linnemann, Hospital Medica Sur, Mexico City, Mexico, along with Florent Ginhoux, A*Star, Singapore, are specifically welcoming intra- and interdisciplinary research on Environmental Immunology, Immunomics, Immunotherapy, including but not restricted to immune aspects of allergies, respiratory tract, skin, autoimmune and neurodegenerative disorders. The editors are looking for cutting-edge scientific research, systematic reviews, well-elaborated clinical cases and case-series. The transfer of information from fundamental research to clinical research and clinical practice – that is from lab bench to bed — is particularly welcome.

“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann.”

“I’m delighted to announce the launch of our new Karger journal, Immune System, committed to advancing the frontiers of immunology by showcasing and pioneering discoveries that unite clinical and preclinical research. Let’s collaboratively shape a future for immunological research, unbound by limitations” says Marco Casola, Publications Manager of Immunology and Allergy.

Submissions will be accepted on a rolling basis via the journal’s homepage at https://karger.com/ims.

SourceKarger
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy